Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Clopidogrel;   Drug: Ticagrelor;   Drug: ASA;   Drug: Placebo
Sponsor:   Medical University of Vienna
Completed - verified April 2014

Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes

Condition:   Acute Coronary Syndromes
Intervention:   Other: blood sample
Sponsor:   Assistance Publique Hopitaux De Marseille
Not yet recruiting - verified April 2014

Copeptin Testing During Pre-hospital Care in the Treatment of Chest Pain Suggestive of Acute Coronary Syndrome

Condition:   Chest Pain
Interventions:   Biological: Blood work in the ambulance;   Biological: Blood work upon arrival in the emergency room;   Biological: Blood work at 3 hours post-arrival in the emergency room
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Not yet recruiting - verified April 2014

The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization

Conditions:   Ischemic Heart Disease;   Myocardial Ischemia;   Coronary Disease;   Acute Coronary Syndrome
Intervention:   Device: AVI® Arsenic trioxide drug eluting stent
Sponsor:   Beijing AmsinoMed Medical Device Co., Ltd
Recruiting - verified April 2014

Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Treatment 3 months DAPT;   Drug: Treatment 12 months DAPT
Sponsor:   Diagram B.V.
Not yet recruiting - verified April 2014

Fluid Status of Outpatients With Dyspnea

Conditions:   Dyspnea,;   Acute Heart Failure Syndrome;   Pulmonary Congestion
Intervention:  
Sponsor:   Intersection Medical, Inc.
Not yet recruiting - verified April 2014

Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS

Condition:   CLOPIDOGREL, POOR METABOLISM of (Disorder)
Interventions:   Drug: genotyping guided therapy Ticagrelor, Clopidogrel;   Drug: standard therapy clopidogrel
Sponsor:   Chinese PLA General Hospital
Not yet recruiting - verified April 2014

Systematic Follow-up of Patients Surviving an Episode of Acute Hypercapnic Respiratory Failure in the ICU

Condition:   Acute Hypercapnic Respiratory Failure
Intervention:  
Sponsors:   Ligue Pulmonaire Genevoise;   University Hospital, Geneva
Recruiting - verified April 2014

Antiplatelet Therapy Following Stent Implantation

Conditions:   Acute Myocardial Infarction;   Coronary Syndrome;   Angina, Unstable
Intervention:  
Sponsor:   Elpen Pharmaceutical Co. Inc.
Recruiting - verified January 2014

The LADIES Acute Coronary Syndromes Study

Conditions:   Acute Coronary Syndromes;   Menopause
Intervention:  
Sponsor:   Arcispedale Santa Maria Nuova-IRCCS
Recruiting - verified April 2014

The Elderly ACS II Trial

Conditions:   Acute Coronary Syndrome;   Coronary Arteriosclerosis;   Myocardial Ischemia;   Cardiovascular Diseases
Interventions:   Drug: prasugrel;   Drug: Clopidogrel
Sponsors:   Arcispedale Santa Maria Nuova-IRCCS;   ANMCO Italian Association of Hospital Cardiologist;   Italian Society of Invasive Cardiology
Recruiting - verified April 2014

Immune Disorder HSCT Protocol

Conditions:   Immune Deficiency Disorders:;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorder:;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
Intervention:   Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
Sponsor:   Washington University School of Medicine
Recruiting - verified April 2014

Tailored Antiplatelet Therapy Following PCI

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome;   Stenosis
Interventions:   Drug: Clopidogrel;   Drug: Ticagrelor;   Genetic: Retrospective Genotype testing;   Genetic: Prospective Genotype testing
Sponsors:   Mayo Clinic;   Applied Health Research Centre (AHRC), Toronto, Canada
Recruiting - verified April 2014

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2014

Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Procedure: ex vivo-expanded cord blood progenitor cell infusion;   Procedure: umbilical cord blood transplantation;   Procedure: double-unit umbilical cord blood transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
Recruiting - verified April 2014

Invasive vs Conservative Strategies in Non-ST-elevation Acute Coronary Syndrome and Comorbidities

Condition:   Acute Coronary Syndrome
Intervention:   Procedure: Coronary angiogram
Sponsors:   University of Valencia;   Instituto de Salud Carlos III
Active, not recruiting - verified April 2014

ProspEctive First Evaluation in Chest Pain Trial

Conditions:   Chest Pain;   Shortness of Breath;   Suspected Acute Coronary Syndrome
Interventions:   Procedure: Coronary CT Angiography;   Procedure: Stress Test
Sponsor:   St. Luke's-Roosevelt Hospital Center
Recruiting - verified May 2012

The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

Condition:   Lung Injury, Acute
Interventions:   Drug: Dose 1 GSK2586881;   Drug: Dose 2 GSK2586881;   Drug: Dose 3 GSK2586881;   Drug: Dose 4 GSK2586881;   Drug: Placebo (saline)
Sponsor:   GlaxoSmithKline
Recruiting - verified April 2014

Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Conditions:   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Secondary Myelodysplastic Syndromes
Interventions:   Drug: azacitidine;   Drug: lenalidomide;   Drug: vorinostat
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified March 2014

Clearance Of Mucus In Stents

Conditions:   Lung Neoplasms;   Respiratory Failure;   Pneumonia;   Acute Coronary Syndromes;   Unstable Angina;   Myocardial Infarction;   Cardiac Arrhythmia;   Thromboembolic Disease
Interventions:   Other: Normal Saline;   Other: Sodium Bicarbonate
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified April 2014

Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel

Condition:   Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Intervention:   Drug: Risk of selected safety events
Sponsor:   AstraZeneca
Recruiting - verified April 2014

A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)

Conditions:   Myelodysplastic Syndromes;   Thrombocytopenia
Intervention:   Drug: Eltrombopag
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2014

BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781);   Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781);   Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781)
Sponsor:   Bayer
Recruiting - verified April 2014

Patient-Centered Adherence Intervention After Acute Coronary Syndrome (ACS) Hospitalization

Condition:   Acute Coronary Syndrome
Interventions:   Behavioral: Intervention;   Behavioral: Usual care
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes
Interventions:   Drug: lenalidomide;   Biological: epoetin alfa;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified April 2014

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts in Transformation
Interventions:   Drug: tipifarnib;   Procedure: clinical observation
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified April 2014

Molecular Epidemiology of ARDS

Conditions:   Acute Respiratory Distress Syndrome;   Lung Diseases
Intervention:  
Sponsors:   Massachusetts General Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2014

Get CardioSmart

You're Invited